Revenue: As of FY2025 Q3, the actual value is USD 7.825 M, missing the estimate of USD 7.981 M.EPS: As of FY2025 Q3, the actual value is USD 0.09, beating the estimate of USD -0.05.EBIT: As of FY2025 Q3, the actual value is USD 2.439 M.<h3>Segment Revenue</h3><ul><li>Umbilical Cord Blood and Cord Tissue Stem Cell Service: Revenue for the nine months ended August 31, 2025, was $23,558,484, compared to $23,716,492 for the same period in 2024.</li><li>PrepaCyte CB: Revenue for the nine months ended August 31, 2025, was $35,785, compared to $39,470 for the same period in 2024.</li><li>Public Cord Blood Banking: Revenue for the nine months ended August 31, 2025, was $128,886, compared to $205,799 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Operating Profit: Total operating profit for the nine months ended August 31, 2025, was $4,449,181, compared to $3,602,631 for the same period in 2024.</li><li>Net Income: Net income for the nine months ended August 31, 2025, was $1,388,048, compared to $2,263,710 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash from Operating Activities: For the nine months ended August 31, 2025, net cash from operating activities was $4,197,793, compared to $3,853,917 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the nine months ended August 31, 2025, net cash used in investing activities was - $685,683, compared to - $3,761,250 for the same period in 2024.</li><li>Net Cash Used in Financing Activities: For the nine months ended August 31, 2025, net cash used in financing activities was - $3,807,863, compared to - $301,297 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue offering cord blood and cord tissue banking services to expectant parents, relying on both online advertising and its national team of field cord blood educators to enroll new clients. A significant portion of new enrollments are generated from returning customers and referrals.</li><li>Non-Core Business: The company has paused further investments related to the Duke License Agreement until the dispute is resolved. The opening of the Cryo-Cell Institute for Cellular Therapies and the proposed spinoff of Celle Corp. are also on hold, pending the outcome of the Duke dispute.</li></ul>

Cryo-Cell | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 7.825 M